Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum IBEX Technologies Inc V.IBT

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a... see more

TSXV:IBT - Post Discussion

IBEX Technologies Inc > Interesting IBT comment on CEO.CA (mid Nov)
View:
Post by guarantor1 on Dec 10, 2021 10:19am

Interesting IBT comment on CEO.CA (mid Nov)

@allahuakbar "this stonk is cheap, but no growth, don't need growth if it's cheap enough"

 
 
0"
Comment by guarantor1 on Dec 10, 2021 11:53am
LOL !! I have heard IBT called a couple of things, But never as "Stonk" But never mind. There will be growth. With Diamine Oxidase And Contract Manufacturing So the whole parameter will be reset, From Value to Growth.. Yadda, Yadda... Bottom Line Right Now = It's grossly underpriced right now.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities